NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that Ron McClurg will retire as Chief Financial Officer effective June 30, 2026, concluding more than five years of service. McClurg will remain with the company as a Senior Advisor through December 31, 2026, to support a smooth transition. Chris Volker, currently NeuroOne’s Chief Operating Officer, will assume the role of CFO on a permanent basis. Additionally, David Wambeke, the newly appointed Chief Business Officer, will take over many of Volker’s current responsibilities.
Volker brings over 25 years of progressive operational and financial leadership experience, particularly in the medical device industry. He is a CFA charterholder and earned his MBA from The Wharton School of the University of Pennsylvania. His background includes senior roles at Abbott, Cardiovascular Systems, Inc. (CSI), and St. Jude Medical. At CSI, he served as Vice President & General Manager of International, overseeing international P&L and commercial expansion. Prior to CSI, Volker held executive leadership roles at St. Jude Medical, reporting directly to the CFO. He began his career in healthcare and technology investment banking at Dain Rauscher.
“On behalf of the entire NeuroOne organization, I want to express our sincere gratitude to Ron for more than five years of outstanding service,” said Dave Rosa, CEO of NeuroOne. “Ron’s retirement marks the culmination of a long and successful career, and we are grateful for his leadership and commitment. We are also fortunate that he will remain actively involved as a Senior Advisor.” Rosa added, “We are pleased to announce the appointment of Chris Volker as our next CFO. Chris brings deep leadership experience across medtech, finance, strategy, and commercial operations, and I believe he is the right person to step into this role as we continue advancing NeuroOne’s technologies and growth strategy.”
McClurg commented, “It has been a privilege to serve as NeuroOne’s CFO for over five years. After many rewarding years in the industry, I have decided the time is right for me to retire. I remain fully committed to supporting NeuroOne through this transition period.” Volker added, “I am honored to take on the role of CFO and appreciate the confidence the Board and management team have placed in me. I look forward to working closely with the team and with Ron during this transition.”
NeuroOne is a medical technology company focused on improving surgical care for neurological disorders. Its electrode technology platform includes four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. The company is also engaged in R&D for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. For more information, visit nmtc1.com.
This leadership change is significant as NeuroOne continues to advance its product pipeline and commercial momentum. The appointment of Volker, with his extensive financial and operational experience, signals the company's commitment to strategic growth and financial discipline. The transition plan ensures continuity, with McClurg advising through year-end.
